AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC ; volume:8 ; number:2 ; year:2021
Advanced science ; 8, Heft 2 (2021)
- Creator
-
Gu, Yu
Lai, Songtao
Dong, Yang
Fu, Hao
Song, Liwei
Chen, Tianxiang
Duan, Yourong
Zhang, Zhen
- DOI
-
10.1002/advs.202002922
- URN
-
urn:nbn:de:101:1-2021020407552644906986
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gu, Yu
- Lai, Songtao
- Dong, Yang
- Fu, Hao
- Song, Liwei
- Chen, Tianxiang
- Duan, Yourong
- Zhang, Zhen
Other Objects (12)
Zeolitic imidazolate framework‐8 as pH‐sensitive nanocarrier for “Arsenic Trioxide” drug delivery
B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC
FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
Effects of FGFR1 Gene Polymorphisms on the Risk of Breast Cancer and FGFR1 Protein Expression
FGFR1-Expression und Genkopienanzahl beim Lungenkarzinom
Activating FGFR1 Mutations in Sporadic Pheochromocytomas
Exosomes: Promising nanocarrier for cancer therapy
FGFR1 wild-type rosette-forming glioneuronal tumours
Untersuchung des unterschiedlichen Therapieansprechens FGFR1-amplifizierter Lungenkrebszellen
Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients
FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer
Temperature- and pH-sensitive nanogels via photocrosslinking
Zeolitic imidazolate framework‐8 as pH‐sensitive nanocarrier for “Arsenic Trioxide” drug delivery
B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC
FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
Effects of FGFR1 Gene Polymorphisms on the Risk of Breast Cancer and FGFR1 Protein Expression
FGFR1-Expression und Genkopienanzahl beim Lungenkarzinom
Activating FGFR1 Mutations in Sporadic Pheochromocytomas
Exosomes: Promising nanocarrier for cancer therapy
FGFR1 wild-type rosette-forming glioneuronal tumours
Untersuchung des unterschiedlichen Therapieansprechens FGFR1-amplifizierter Lungenkrebszellen
Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients
FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer
Temperature- and pH-sensitive nanogels via photocrosslinking
Zeolitic imidazolate framework‐8 as pH‐sensitive nanocarrier for “Arsenic Trioxide” drug delivery
B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC
FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
Effects of FGFR1 Gene Polymorphisms on the Risk of Breast Cancer and FGFR1 Protein Expression
FGFR1-Expression und Genkopienanzahl beim Lungenkarzinom
Activating FGFR1 Mutations in Sporadic Pheochromocytomas
Exosomes: Promising nanocarrier for cancer therapy
FGFR1 wild-type rosette-forming glioneuronal tumours
Untersuchung des unterschiedlichen Therapieansprechens FGFR1-amplifizierter Lungenkrebszellen
Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients
FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer